MADRIGAL PHARMACEUTICALS, INC. (MDGL) — Institutional Holders, Q2 2026 (page 5)

417 institutional investment managers reported a MDGL position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $12.7B. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 401 to 417. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

MDGL 13F holders ranked 401–417 of 417

Institutional investors reporting a position in MADRIGAL PHARMACEUTICALS, INC. on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
Institute for Wealth Management#401 · 2 sh$1.1KNew
TD PRIVATE CLIENT WEALTH#402 · 2 sh$1.1KNew
Stone House Investment Management#403 · 2 sh$1.1KNew
Bogart Wealth#404 · 2 sh$1.1K+100.0%
Kilter Group#405 · 2 sh$1.1K-33.3%
SouthState Bank#406 · 2 sh$1.1K0.0%
HANTZ FINANCIAL SERVICES#407 · 1 sh$1.0K0.0%
CX Institutional#408 · 2 sh$1.0K0.0%
Physician Wealth Advisors#409 · 1 sh$537.00-50.0%
TFC Financial Management#410 · 1 sh$537.000.0%
Ronald Blue#411 · 1 sh$537.000.0%
Buck Wealth Strategies#412 · 1 sh$537.00New
Caitlin John#413 · 1 sh$537.00-50.0%
Essential Partners#414 · 1 sh$537.00New
NOMURA ASSET MANAGEMENT LTD#415 · 0 sh$0.00New
Compagnie Lombard Odier SCmA#416 · 0 sh$0.00-100.0%
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#417 · 17,197 sh—+0.9%

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.